Carcinoid Syndrome News and Research

RSS
New targeted treatment could benefit patients with certain pancreatic tumors

New targeted treatment could benefit patients with certain pancreatic tumors

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Lexicon Pharmaceuticals' revenues decrease to $0.4 million in second quarter 2015

Lexicon Pharmaceuticals' revenues decrease to $0.4 million in second quarter 2015

Lexicon updates drug development progress, reports 2014 financial results

Lexicon updates drug development progress, reports 2014 financial results

Lexicon announces pricing of underwritten public offering of common stock

Lexicon announces pricing of underwritten public offering of common stock

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

Ipsen seeks marketing authorization from FDA for Somatuline Depot 120mg injection

Ipsen seeks marketing authorization from FDA for Somatuline Depot 120mg injection

Ipsen submits Supplemental New Drug Application to FDA for Somatuline Depot 120mg injection

Ipsen submits Supplemental New Drug Application to FDA for Somatuline Depot 120mg injection

Joint initiative aims to eradicate health disparities among communities of color in the U.S.

Joint initiative aims to eradicate health disparities among communities of color in the U.S.

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Lexicon receives FDA Fast Track status for development of LX1033 for irritable bowel syndrome

Lexicon receives FDA Fast Track status for development of LX1033 for irritable bowel syndrome

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Lexicon announces results from two initial trials of LX4211 for type 2 diabetes

Lexicon announces results from two initial trials of LX4211 for type 2 diabetes

Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes

Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes

Lexicon presents six posters on LX4211 at ADA meeting

Lexicon presents six posters on LX4211 at ADA meeting